Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

B cell and B cell-related pathways for novel cancer treatments.

Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ.

Cancer Treat Rev. 2019 Feb;73:10-19. doi: 10.1016/j.ctrv.2018.12.001. Epub 2018 Dec 3. Review.

PMID:
30551036
2.

PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.

Hu C, Xiong J, Zhang L, Huang B, Zhang Q, Li Q, Yang M, Wu Y, Wu Q, Shen Q, Gao Q, Zhang K, Sun Z, Liu J, Jin Y, Tan J.

Cell Mol Immunol. 2004 Aug;1(4):280-94.

3.

Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.

Weinstein AM, Storkus WJ.

Adv Cancer Res. 2015;128:197-233. doi: 10.1016/bs.acr.2015.04.003. Epub 2015 May 5. Review.

4.

IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.

Pimenta EM, De S, Weiss R, Feng D, Hall K, Kilic S, Bhanot G, Ganesan S, Ran S, Barnes BJ.

Immunol Cell Biol. 2015 May-Jun;93(5):486-99. doi: 10.1038/icb.2014.110. Epub 2014 Dec 23.

PMID:
25533286
5.

Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Ebert LM, Schaerli P, Moser B.

Mol Immunol. 2005 May;42(7):799-809. Epub 2004 Nov 23. Review.

PMID:
15829268
6.

CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking.

Wiener A, Schippers A, Wagner N, Tacke F, Ostendorf T, Honke N, Tenbrock K, Ohl K.

Clin Exp Immunol. 2016 Jul;185(1):22-32. doi: 10.1111/cei.12791. Epub 2016 Apr 18.

7.

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.

Nicholas NS, Apollonio B, Ramsay AG.

Biochim Biophys Acta. 2016 Mar;1863(3):471-482. doi: 10.1016/j.bbamcr.2015.11.003. Epub 2015 Nov 7. Review.

8.

The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy.

Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y.

Int Immunopharmacol. 2016 Jul;36:73-85. doi: 10.1016/j.intimp.2016.04.018. Epub 2016 Apr 22. Review.

PMID:
27111515
9.

Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?

Reilly RT, Emens LA, Jaffee EM.

Curr Opin Investig Drugs. 2001 Jan;2(1):133-5. Review.

PMID:
11527005
10.

Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.

He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Karnowski A, Belz GT, Ghali JR, Cook MC, Riminton DS, Veillette A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li Z, Yu D.

Immunity. 2013 Oct 17;39(4):770-81. doi: 10.1016/j.immuni.2013.09.007.

11.

Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?

Siliņa K, Rulle U, Kalniņa Z, Linē A.

Cancer Immunol Immunother. 2014 Jul;63(7):643-62. doi: 10.1007/s00262-014-1544-9. Epub 2014 Apr 3. Review.

PMID:
24695950
12.

A novel mouse model for tracking the fate of CXCR5-expressing T cells.

Takebe T, Sakamoto K, Higami Y, Harada Y.

Biochem Biophys Res Commun. 2018 Jan 8;495(2):1642-1647. doi: 10.1016/j.bbrc.2017.12.029. Epub 2017 Dec 6.

PMID:
29223395
13.

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.

Sasidharan Nair V, Elkord E.

Immunol Cell Biol. 2018 Jan;96(1):21-33. doi: 10.1111/imcb.1003. Epub 2017 Nov 17. Review. Erratum in: Immunol Cell Biol. 2018 Feb;96(2):236.

PMID:
29359507
14.

Aberrant Humoral Immune Responses in Neurosyphilis: CXCL13/CXCR5 Play a Pivotal Role for B-Cell Recruitment to the Cerebrospinal Fluid.

Yu Q, Cheng Y, Wang Y, Wang C, Lu H, Guan Z, Huang J, Gong W, Shi M, Ni L, Wu J, Peng R, Zhou P.

J Infect Dis. 2017 Sep 1;216(5):534-544. doi: 10.1093/infdis/jix233.

PMID:
28931218
15.

Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors.

Müller G, Höpken UE, Stein H, Lipp M.

J Leukoc Biol. 2002 Jul;72(1):1-8. Review.

PMID:
12101256
16.

Functional interactions between B lymphocytes and the innate immune system.

Lampropoulou V, Shen P, Hilgenberg E, Ries S, Opitz C, Fillatreau S.

Infect Disord Drug Targets. 2012 Jun;12(3):191-9. Review.

PMID:
22394177
17.

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C.

Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405. Review.

PMID:
27088920
18.

CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses.

Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, Sallusto F, Tangye SG, Mackay CR.

J Immunol. 2011 May 15;186(10):5556-68. doi: 10.4049/jimmunol.1002828. Epub 2011 Apr 6.

19.

Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.

Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4.

20.

Humoral immunity, inflammation and cancer.

Tan TT, Coussens LM.

Curr Opin Immunol. 2007 Apr;19(2):209-16. Epub 2007 Feb 2. Review.

PMID:
17276050

Supplemental Content

Support Center